FDA approves Outlook Therapeutics' ONS-5010?
Recent trades
25- 0x3c76…d4ee BUY Yes $158.84 1h ago
- 0xd12f…e85a BUY Yes $714.21 2h ago
- 0x4a74…7a5c SELL Yes $0.94 Jul 20
- 0x7a41…a18f BUY No $1.00 Jul 17
- 0x1cdf…7363 SELL Yes $0.97 Jul 17
- 0xd8e1…331c SELL Yes $0.97 Jul 17
- 0xf331…2520 SELL Yes $0.97 Jul 17
- 0x08da…239a SELL Yes $0.97 Jul 17
- 0x50ee…f50b SELL Yes $0.97 Jul 17
- 0xc5a8…6095 SELL Yes $0.97 Jul 17
- 0xfef9…759b SELL Yes $0.97 Jul 17
- 0x2f77…7a87 SELL Yes $0.97 Jul 17
- 0xf8d9…6254 SELL Yes $0.97 Jul 17
- 0x9db9…cfc8 SELL Yes $0.97 Jul 17
- 0x1cdf…7363 BUY Yes $1.00 Jul 17
- 0xf8d9…6254 BUY Yes $1.00 Jul 17
- 0x08da…239a BUY Yes $1.00 Jul 17
- 0xd8e1…331c BUY Yes $1.00 Jul 17
- 0xfef9…759b BUY Yes $1.00 Jul 17
- 0x50ee…f50b BUY Yes $1.00 Jul 17
- 0x9db9…cfc8 BUY Yes $1.00 Jul 17
- 0x2f77…7a87 BUY Yes $1.00 Jul 17
- 0xc5a8…6095 BUY Yes $1.00 Jul 17
- 0xf331…2520 BUY Yes $1.00 Jul 17
- 0x91d7…5f2e BUY Yes $1.00 Jul 17
As of market creation, the FDA's expected decision date for the specified application is July 29, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Outlook Therapeutics's ONS-5010 as a treatment for wet age-related macular degeneration by August 12, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Comments